title: Sulforaphene-Carboplatin Combination Synergistically Enhances Apoptosis by Disruption of Mitochondrial Membrane Potential and Cell Cycle Arrest in Human Non-Small Cell Lung Carcinoma.
abstract: Worldwide non-small cell lung cancer (NSCLC) causes substantial morbidity and mortality among human populations. Due to the severe side effects and low survival rate of patients with the conventional drugs, implementation of new combination therapies is much needed. The aim of this study was to evaluate the efficacy of a combination therapy with a conventional drug and a natural medicine. We compared the combination of chemotherapy drug carboplatin and the radish-derived isothiocyanate compound sulforaphene, which synergistically induces higher apoptosis and growth inhibition in A549, to the drug alone in human NSCLC cells. We found that this combination group significantly induced higher depolarization of mitochondrial membrane potential (MMP) and intracellular reactive oxygen species generation than the single drug dose, followed by cell cycle arrest at the G0/G1 phase after 24 h of incubation. In addition to that, the Western blot assays showed that combination treatment inhibited the expression of Bcl-2 and successively upregulated the expression of Bax, cytochrome C, apoptosis-inducing factor, caspase-9 and -3, and cleaved poly ADP ribose polymerase. It also modulated the expression of PI3K, p-extracellular signal-regulated kinase (1/2), and p-c-Jun N-terminal kinase indicating the involvement of antiproliferative properties. Further pretreatment with pan-caspase inhibitor Z-VAD-fmk was carried out to confirm the effect of caspases in the combination therapy-induced apoptosis. To summarize, this is the first report that sulforaphene-carboplatin combination treatment synergistically promotes enhanced apoptosis and antiproliferative effect over single drug treatment against A549, human NSCLC cells through caspase activation, MMP disruption, and cell cycle arrest. This study demonstrates that the duel character of this combination therapy may be an effective replacement for conventional therapy alone against NSCLC.
authors.affiliation: 1 Beckman Laser Institute Korea, Dankook University , Cheonan, Republic of Korea.
authors.forename: Saswata
authors.initials: S
authors.lastname: Chatterjee
authors.affiliation: 1 Beckman Laser Institute Korea, Dankook University , Cheonan, Republic of Korea.
authors.forename: Yun-Hee
authors.initials: YH
authors.lastname: Rhee
authors.affiliation: 1 Beckman Laser Institute Korea, Dankook University , Cheonan, Republic of Korea.|2 Department of Biomedical Science, Dankook University , Cheonan, Republic of Korea.|3 Biomedical Translational Research Institute, Dankook University , Cheonan, Republic of Korea.
authors.forename: Jin-Chul
authors.initials: JC
authors.lastname: Ahn
mesh_terms: D000072283:A549 Cells; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis; D015415:Biomarkers / Q000378:metabolism; D016190:Carboplatin / Q000494:pharmacology* / Q000627:therapeutic use; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D049109:Cell Proliferation; D004338:Drug Combinations; D004357:Drug Synergism; D006801:Humans; D017879:Isothiocyanates / Q000494:pharmacology* / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism; D008564:Membrane Potentials / Q000187:drug effects; D051336:Mitochondrial Membranes / Q000187:drug effects* / Q000502:physiology; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D031224:Raphanus / Q000737:chemistry*; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy / Q000378:metabolism; D013454:Sulfoxides
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D015415:Biomarkers; D004338:Drug Combinations; D017879:Isothiocyanates; D010936:Plant Extracts; D013454:Sulfoxides; D016190:Carboplatin; C016766:sulforaphane
keywords: apoptosis; carboplatin; combination; non-small cell lung cancer; sulforaphene; synergism